🟢 Humacyte is trading 11.5% up today after Lancet publication of positive V007 Phase 3 results

Humacyte is trading 11.5% up now at $0.65 after August 19, 2026 publication of one-year V007 Phase 3 results in The Lancet Digital Health.

• The peer-reviewed study reported the bioengineered vessel outperformed standard arteriovenous fistulas after one year, particularly among women and high-risk patients.
• Company-specific clinical validation is the strongest apparent catalyst, with broader biotechnology strength providing additional support.